Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer.
Debie Y, Van Audenaerde JRM, Vandamme T, Croes L, Teuwen LA, Verbruggen L, Vanhoutte G, Marcq E, Verheggen L, Le Blon D, Peeters B, Goossens ME, Pannus P, Ariën KK, Anguille S, Janssens A, Prenen H, Smits ELJ, Vulsteke C, Lion E, Peeters M, van Dam PA.
Debie Y, et al. Among authors: prenen h.
Clin Cancer Res. 2023 Feb 1;29(3):635-646. doi: 10.1158/1078-0432.CCR-22-2185.
Clin Cancer Res. 2023.
PMID: 36341493